Why is the Cochlear share price tumbling 5% on Tuesday?

Cochlear shares are copping a belting this Tuesday from spooked investors.

| More on:
a woman puts her fingers in her ears with a pained expression on her face with her eyes closed as though trying to block hearing bad news or an unpleasant loud noise.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

It's been a pretty awful day for the S&P/ASX 200 Index (ASX: JXO) and most ASX 200 shares so far this Tuesday. At present, the ASX 200 has slid by 0.52% and is back to around 7,585 points. But it's been far worse for the Cochlear Limited (ASX: COH) share price.

Cochlear shares are having a horrid day. This ASX 200 healthcare stock and medical device manufacturer closed at $308.45 a share yesterday. But this morning, Cochlear shares opened at $301.74 and are currently down a significant 5.55% to just $291.33 a share.

So what's going on with Cochlear shares this Tuesday that has elicited such a dramatic, and market-trailing, loss for investors?

Why has this ASX 200 healthcare stock just tanked 5%?

Well, unfortunately, we can't know for sure. There has been no news or announcements out of Cochlear itself today that might explain this sizeable share price drop. Indeed, we haven't seen any fresh news out of the company since 12 January.

However, there has been some other news out today that might be playing a role here.

According to reporting in The Australian, an ASX broker has dramatically downgraded its opinions on Cochlear shares.

As reported, broker UBS has lowered its rating on Cochlear from neutral to sell. The broker has also reduced its share price target for the company by 7.7% to $240 a share. If realised, this would see the Cochlear share price lose another 17.7% from where the company is currently trading at.

Here's what UBS analyst Laura Sutcliffe was quoted as saying to explain this move:

The market seems to be ignoring the possible impact to Cochlear's implant sales from a potential vaccine against CMV [cytomegalovirus], a virus transmitted in utero that accounts for an estimated 20 per cent of childhood deafness… Our work with experts suggests a good chance of success, meaning 5-6 per cent of our prior Cochlear revenue estimates could be at risk.

This could well be what has spooked investors today. A long-term threat to Cochlear's business model is obviously not something that shareholders relish. Even if this vaccine news leads to better outcomes for humanity, investors have to value Cochlear's financials above everything else.

Cochlear share price snapshot

Despite today's chunky sell-off, the Chochlear share price has remained a fairly lucrative investment for anyone who has held the company for longer than a few months. At today's pricing, Cochlear remains up a healthy 32.3% over the past 12 months, and up 46.5% over the past five years.

At the current share price, Cochlear is trading with a market capitalisation of $19.96 billion and a dividend yield of 1.13%.

Motley Fool contributor Sebastian Bowen has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Cochlear. The Motley Fool Australia has recommended Cochlear. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a young woman holds her hand to her ear and leans sideways as if to listen to something that's surprising her as her eyes and her mouth are wide open.
Healthcare Shares

Down 15% since January, are Cochlear shares now a buy?

Let's see what analysts are saying about this blue chip.

Read more »

Green arrow with green stock prices symbolising a rising share price.
Healthcare Shares

Guess which popular ASX 200 stock is up nearly 60% in less than 2 months?

Investors who bought this ASX 200 stock in the recent dip have been strongly rewarded.

Read more »

A senior pharmacist talks to a customer at the counter in a shop.
Healthcare Shares

Are Sigma Healthcare shares a good buy now after the merger with Chemist Warehouse?

Sigma Healthcare shares have soared 154% in 12 months. Can this stellar run continue?

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

Up 34% since April, ASX 300 healthcare stock lifts off again today on new milestone

The ASX 300 healthcare stock has been on a tear since hitting one-year lows in April.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

Should I buy the dip on CSL shares?

A leading fund manager gives his verdict on the growth prospects for CSL shares.

Read more »

A woman relaxes on a yellow couch with a book and cuppa, and looks pensively away as she contemplates the joy of earning passive income.
Healthcare Shares

NIB shares have soared 24% this year. Does Macquarie expect this to continue?

Will this private health insurer continue to deliver big returns? Let's find out.

Read more »

Woman presenting financial report on large screen in conference room.
Healthcare Shares

Up nearly 30% in a year, should I buy Fisher & Paykel shares before its earnings result?

Will the ASX 200 healthcare stock continue to outperform?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

CSL shares among most expensive on ASX. Is now a good time to buy?

Analysts predict CSL share price growth will keep on coming.

Read more »